{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:47:23Z","timestamp":1792691243641,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bmc.2025.118247","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T19:16:32Z","timestamp":1747768592000},"page":"118247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Recent breakthroughs in synthetic small molecules targeting SARS-CoV-2 Mpro from 2022 to 2024"],"prefix":"10.1016","volume":"128","author":[{"given":"Laura","family":"Braconi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Sosic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3473-2683","authenticated-orcid":false,"given":"Letizia","family":"Crocetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118247_b0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"Vkovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.bmc.2025.118247_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117909","article-title":"Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: structure-activity relationships","volume":"113","author":"Kerti","year":"2024","journal-title":"Bioorganic Med Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115491","article-title":"The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022","volume":"257","author":"Pang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113201","article-title":"RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic","volume":"213","author":"Tian","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105697","article-title":"Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication","volume":"217","author":"Corona","year":"2023","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bmc.2025.118247_b0030","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bmc.2025.118247_b0035","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.bmc.2025.118247_b0040","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118247_b0045","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118247_b0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.bmc.2025.118247_b0055","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1021\/acs.jmedchem.2c01005","article-title":"Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure-activity relationship insights and evolution perspectives","volume":"65","author":"La Monica","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorganic Med Chem Lett."},{"key":"10.1016\/j.bmc.2025.118247_b0065","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.3390\/ijms24043236","article-title":"Identification of SARS-CoV-2 main protease (Mpro) cleavage sites using two-dimensional electrophoresis and in silico cleavage site prediction","volume":"24","author":"Miltner","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bmc.2025.118247_b0070","doi-asserted-by":"crossref","first-page":"9523","DOI":"10.3390\/ijms21249523","article-title":"Identification of host cellular protein substrates of SARS-CoV-2 main protease","volume":"21","author":"Miczi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bmc.2025.118247_b0075","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202000246","article-title":"N-terminomics for the identification of in vitro substrates and cleavage site specificity of the SARS-CoV-2 main protease","volume":"21","author":"Koudelka","year":"2021","journal-title":"Proteomics."},{"key":"10.1016\/j.bmc.2025.118247_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109892","article-title":"Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome","volume":"37","author":"Pablos","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.bmc.2025.118247_b0085","article-title":"Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ."},{"key":"10.1016\/j.bmc.2025.118247_b0090","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0095","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1021\/acs.jmedchem.2c00624","article-title":"S\u2011217622, a 3CL protease inhibitor and clinical candidate for SARS-CoV\u20112","volume":"65","author":"Tyndall","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0100","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00840-23","article-title":"Evaluation of in vitro antiviral activity of SARS-CoV-2 Mpro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions","volume":"67","author":"Tong","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bmc.2025.118247_b0105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.medj.2023.12.004","article-title":"Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19","volume":"5","author":"Mao","year":"2024","journal-title":"Med."},{"key":"10.1016\/j.bmc.2025.118247_b0110","doi-asserted-by":"crossref","first-page":"13550","DOI":"10.1021\/acs.jmedchem.3c02469","article-title":"A second-generation oral SARS-CoV-2 main protease inhibitor clinical candidate for the treatment of COVID-19","volume":"67","author":"Allerton","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0115","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of Coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0120","article-title":"Discovery of a novel inhibitor of Coronavirus 3CL protease for the potential treatment of COVID-19","author":"Boras","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.bmc.2025.118247_b0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.freeradbiomed.2020.06.032","article-title":"Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections","volume":"156","author":"Sies","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bmc.2025.118247_b0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijsu.2020.10.018","article-title":"Ebselen, a new candidate therapeutic against SARS-CoV-2","volume":"84","author":"Haritha","year":"2020","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.bmc.2025.118247_b0135","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1126\/science.abg5827","article-title":"Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2","volume":"373","author":"Drayman","year":"2021","journal-title":"Science."},{"key":"10.1016\/j.bmc.2025.118247_b0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13063-021-05951-w","article-title":"Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol","volume":"23","author":"Mera-Cordero","year":"2022","journal-title":"Trials."},{"key":"10.1016\/j.bmc.2025.118247_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107380","article-title":"Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review","volume":"147","author":"Xiao","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0150","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/acs.jcim.1c00851","article-title":"High-throughput virtual screening and validation of a SARS-CoV-2 main protease noncovalent inhibitor","volume":"62","author":"Clyde","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bmc.2025.118247_b0155","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","article-title":"Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high target specificity and low toxicity","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0160","doi-asserted-by":"crossref","first-page":"16902","DOI":"10.1021\/acs.jmedchem.2c01716","article-title":"Discovery and crystallographic studies of nonpeptidic piperazine derivatives as covalent SARS-CoV-2 main protease inhibitors","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0165","doi-asserted-by":"crossref","first-page":"16426","DOI":"10.1021\/acs.jmedchem.3c01876","article-title":"Design, synthesis, and biological evaluation of trisubstituted piperazine derivatives as noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 main protease inhibitors with improved antiviral activity and favorable druggability","volume":"66","author":"Gao","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114130","article-title":"In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease","volume":"231","author":"Xiong","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114508","article-title":"Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease","volume":"238","author":"Dou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077460","article-title":"Identification of semicarbazones, thiosemicarbazones and triazine nitriles as inhibitors of Leishmania mexicana cysteine protease CPB","volume":"8","author":"Schr\u00f6der","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.bmc.2025.118247_b0185","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1021\/acsinfecdis.0c00325","article-title":"A coumarin-based analogue of thiacetazone as dual covalent inhibitor and potential fluorescent label of HadA in Mycobacterium tuberculosis","volume":"7","author":"Farjallah","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bmc.2025.118247_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115129","article-title":"Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2","volume":"249","author":"Ren","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0195","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm049337s","article-title":"Synthesis and biological evaluation of a new series of 2,3,5-substituted [1,2,4]-thiadiazoles as modulators of adenosine A1 receptors and their molecular mechanism of action","volume":"48","author":"G\u00f6bly\u00f6s","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0200","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/sj.bjp.0706624","article-title":"The \u201callosteric modulator\u201d SCH-202676 disrupts G protein-coupled receptor function via sulphydryl-sensitive mechanisms","volume":"147","author":"Lewandowicz","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bmc.2025.118247_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115721","article-title":"Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19","volume":"260","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0210","article-title":"Nature-inspired catalytic asymmetric rearrangement of cyclopropylcarbinyl cation","volume":"9","author":"Li","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bmc.2025.118247_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129238","article-title":"Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors","volume":"86","author":"Guo","year":"2023","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2025.118247_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115720","article-title":"Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur","volume":"260","author":"Kang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0225","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/molecules28020514","article-title":"Discovery of a novel trifluoromethyl diazirine inhibitor of SARS-CoV-2 Mpro","volume":"28","author":"Citarella","year":"2023","journal-title":"Molecules."},{"key":"10.1016\/j.bmc.2025.118247_b0230","doi-asserted-by":"crossref","first-page":"9376","DOI":"10.1021\/acs.jmedchem.2c00636","article-title":"Small-molecule thioesters as SARS-CoV-2 main protease inhibitors: enzyme inhibition, structure-activity relationships, antiviral activity, and X-ray structure determination","volume":"65","author":"Pillaiyar","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128867","article-title":"Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease","volume":"72","author":"Deodato","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2025.118247_b0240","article-title":"Discovery of 3-oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin derivatives as SARS-CoV-2 main protease inhibitors through virtual screening and biological evaluation","volume":"97","author":"Dou","year":"2023","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2025.118247_b0245","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","article-title":"Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL protease (SARS-CoV-2 3CLpro)","volume":"65","author":"Han","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115487","article-title":"Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro)","volume":"257","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0255","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1021\/acs.jmedchem.1c02214","article-title":"Penicillin derivatives inhibit the SARS-CoV-2 main protease by reaction with its nucleophilic cysteine","volume":"65","author":"Malla","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0260","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1039\/D0CC06870E","article-title":"Mass spectrometry reveals potential of \u03b2-lactams as SARS-CoV-2 Mpro inhibitors","volume":"57","author":"Malla","year":"2021","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bmc.2025.118247_b0265","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1039\/D3OB00381G","article-title":"Synthesis of SARS-CoV-2 Mpro inhibitors bearing a cinnamic ester warhead with in vitro activity against human coronaviruses","volume":"21","author":"Citarella","year":"2023","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0270","doi-asserted-by":"crossref","first-page":"26895","DOI":"10.1039\/D2RA04015H","article-title":"In vitro and computational investigations of novel synthetic carboxamide-linked pyridopyrrolopyrimidines with potent activity as SARS-CoV-2-Mpro inhibitors","volume":"12","author":"Aljuhani","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.bmc.2025.118247_b0275","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejmech.2017.09.010","article-title":"Characterization and structure-activity relationship study of iminodipyridinopyrimidines as novel hepatitis C virus inhibitor","volume":"140","author":"Park","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129407","article-title":"Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV-2 main protease","volume":"92","author":"Wang","year":"2023","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2025.118247_b0285","doi-asserted-by":"crossref","first-page":"12266","DOI":"10.1021\/acs.jmedchem.3c00818","article-title":"Discovery and mechanism study of SARS-CoV-2 3C-like protease inhibitors with a new reactive group","volume":"66","author":"Ren","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0290","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1021\/acs.jmedchem.0c01137","article-title":"Design and characterization of an intracellular covalent ligand for CC chemokine receptor 2","volume":"64","author":"Ortiz Zacar\u00edas","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0295","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-021-23313-7","article-title":"Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives","volume":"12","author":"Amporndanai","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bmc.2025.118247_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsb.2020.107575","article-title":"SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3","volume":"211","author":"Griffin","year":"2020","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.bmc.2025.118247_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117531","article-title":"Identification of Ebselen derivatives as novel SARS-CoV-2 main protease inhibitors: design, synthesis, biological evaluation, and structure-activity relationships exploration","volume":"96","author":"Zhang","year":"2023","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0310","doi-asserted-by":"crossref","first-page":"16922","DOI":"10.1021\/acs.jmedchem.1c00409","article-title":"Perspectives on SARS-CoV-2 main protease inhibitors","volume":"64","author":"Gao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105455","article-title":"The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus","volume":"117","author":"Qiao","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106830","article-title":"Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease","volume":"140","author":"Liu","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0325","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1021\/acs.jmedchem.1c00566","article-title":"Discovery and mechanism of SARS-CoV-2 main protease inhibitors","volume":"65","author":"Huff","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104889","article-title":"Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals","volume":"112","author":"Sun","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128526","article-title":"Discovery of highly potent SARS-CoV-2 Mpro inhibitors based on benzoisothiazolone scaffold","volume":"58","author":"Chen","year":"2022","journal-title":"Bioorganic Med Chem Lett."},{"key":"10.1016\/j.bmc.2025.118247_b0340","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100582","article-title":"Structure-activity studies reveal scope for optimisation of Ebselen-type inhibition of SARS-CoV-2 main protease","volume":"17","author":"Thun-Hohenstein","year":"2022","journal-title":"ChemMedChem."},{"key":"10.1016\/j.bmc.2025.118247_b0345","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3390\/ijms25020971","article-title":"Leveraging SARS-CoV-2 main protease (Mpro) for COVID-19 mitigation with selenium-based inhibitors","volume":"25","author":"De Luca","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bmc.2025.118247_b0350","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s42003-022-03090-9","article-title":"Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay","volume":"5","author":"Narayanan","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bmc.2025.118247_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114046","article-title":"Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors","volume":"229","author":"Stille","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0360","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1039\/D1SC06596C","article-title":"Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide","volume":"13","author":"Yamane","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bmc.2025.118247_b0365","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-023-01392-w","article-title":"A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bmc.2025.118247_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115657","article-title":"Discovery and structure-activity relationship studies of novel \u03b1-ketoamide derivatives targeting the SARS-CoV-2 main protease","volume":"259","author":"Huang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115667","article-title":"Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors","volume":"259","author":"Tan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0380","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/jacs.1c08402","article-title":"Ultralarge virtual screening identifies SARS-CoV-2 main protease inhibitors with broad-spectrum activity against Coronaviruses","volume":"144","author":"Luttens","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bmc.2025.118247_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115563","article-title":"Spiroindole-containing compounds bearing phosphonate group of potential Mpro-SARS-CoV-2 inhibitory properties","volume":"258","author":"Bekheit","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0390","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.3390\/molecules27206934","article-title":"Potential therapeutic approach of melatonin against Omicron and some other variants of SARS-CoV-2","volume":"27","author":"Begum","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.bmc.2025.118247_b0395","doi-asserted-by":"crossref","first-page":"13880","DOI":"10.1038\/s41598-022-17883-9","article-title":"Development of spiro-3-indolin-2-one containing compounds of antiproliferative and anti-SARS-CoV-2 properties","volume":"12","author":"Fawazy","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bmc.2025.118247_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105131","article-title":"3-Alkenyl-2-oxindoles: synthesis, antiproliferative and antiviral properties against SARS-CoV-2","volume":"114","author":"Girgis","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0405","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1016\/j.sjbs.2021.02.059","article-title":"Screening of drug databank against WT and mutant main protease of SARS-CoV-2: towards finding potential compound for repurposing against COVID-19","volume":"28","author":"Sharma","year":"2021","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.bmc.2025.118247_b0410","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade8778","article-title":"Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors","volume":"9","author":"Moghadasi","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bmc.2025.118247_b0415","doi-asserted-by":"crossref","first-page":"11522","DOI":"10.1021\/acs.jmedchem.4c00384","article-title":"New strategies for responding to SARS-CoV-2: the present and future of dual-target drugs","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0420","doi-asserted-by":"crossref","first-page":"16252","DOI":"10.1021\/acs.jmedchem.2c00954","article-title":"Structure-based design of a dual-targeted covalent inhibitor against papain-like and main proteases of SARS-CoV-2","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0425","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2024.2301772","article-title":"Identification and evaluation of antiviral activity of novel compounds targeting SARS-CoV-2 virus by enzymatic and antiviral assays, and computational analysis","volume":"39","author":"Nem\u010dovi\u010dov\u00e1","year":"2024","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0430","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13578-021-00564-x","article-title":"Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases","volume":"11","author":"Chen","year":"2021","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bmc.2025.118247_b0435","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1016\/j.apsb.2022.07.017","article-title":"Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19","volume":"12","author":"Yi","year":"2022","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.bmc.2025.118247_b0440","first-page":"4538","article-title":"Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease","volume":"10","author":"Wang","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bmc.2025.118247_b0445","article-title":"MPI8 is potent against SARS-CoV-2 by inhibiting dually and selectively the SARS-CoV-2 main protease and the host cathepsin L","volume":"17","author":"Ma","year":"2022","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118247_b0450","doi-asserted-by":"crossref","first-page":"21035","DOI":"10.1021\/jacs.2c04626","article-title":"Dual inhibitors of main protease (Mpro) and cathepsin L as potent antivirals against SARS-CoV-2","volume":"144","author":"Mondal","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bmc.2025.118247_b0455","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625001889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625001889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:37:14Z","timestamp":1775097434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625001889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":91,"alternative-id":["S0968089625001889"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118247","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent breakthroughs in synthetic small molecules targeting SARS-CoV-2 Mpro from 2022 to 2024","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118247"}}